Eric Winquist
Papers
8
Total Citations
849
H-Index
7
About
Eric Winquist is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the treatment landscape for oropharyngeal squamous cell carcinoma (OPSCC). His primary research areas focus on the comparative effectiveness of radiotherapy versus transoral robotic surgery (TORS) for early-stage disease. Winquist is best known as the principal investigator of the landmark ORATOR trial, a phase 2 randomized study that directly compared these two curative-intent modalities. The primary publication (2019, 458 citations) and its final results (2024) provide critical, high-level evidence on survival, toxicity, and quality of life outcomes, challenging assumptions and guiding clinical decision-making. His systematic review (174 citations) further synthesized the existing literature on this debate. Beyond clinical trials, Winquist has contributed to translational research, including high-throughput drug testing in HPV-positive and negative head and neck cancers. His work, encompassing over 800 total citations, has been instrumental in defining modern, evidence-based treatment paradigms for oropharyngeal cancer, directly impacting patient counseling and therapeutic strategy at tertiary care institutions worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8